TTCyto is lmmunowake's proprietary platform focused on developing safe, next-generaion immunocyntokines. Our goal is to develop immune agonists capable of overcoming inhibitory signals. Naturally, the immune systems tightly regulates between the "gas pedal" and "breaks" through a variety of mechanisms, including cytokines and signaling molecules. Agonist-based drugs can throw off this delicate balance by adding too much "gas" and induce significant systemic toxicity. Therefore, the primary barrier for antagonists must overcome is must toxicity. The ideal agonist should activate inside the tumor microenvironment, but not the systemic immune system.
